Kwath in gout (increased uric acid)

Role of Trivritadi kwath in vatrakta (Gout)

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2020/04/024821

Enrollment

Registered

2020-04-23

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: M200- Deformity of finger(s)

Interventions

Intervention1: Role of Trivritadi kwath in vatarakta: Content of trivritadi kwath:- trivrit mool,vidarikand,gokshure Dose: 40ml BD Oral route of adminstration Duration of study: 45days Intervention2:

Eligibility

Inclusion criteria

Inclusion criteria: 1. Patient having symptoms of Vatarakta. 2. Patient willing to participate in the trial and with informed consent

Exclusion criteria

Exclusion criteria: 1.Pateints with age of 60 years 2.Known case of Septic arthritis, osteoarthritis, rheumatoid arthritis. 3.Known case of Severe systemic multi organ failure 4.Patient with secondary hyperuricemia (i.e., patient on ATT, chemotherapy) 5.Patient with uncontrolled diabetes. 6.Patients with renal impairment. 7.Patients with autoimmune disease (i.e., patient of RA, psoriasis)

Design outcomes

Primary

Measure	Time frame
Improvement in all symptoms of goutTimepoint: 6 weeks	—

Secondary

Measure	Time frame
Hb%, TLC, DLC, ESR, serum uric acid, blood sugar, serum creatinin, blood urea, urine (routine and microscopic)Timepoint: 6 weeks	—

Countries

India

Contacts

Public ContactArchana arya

Rishikul ayurvedic college haridwar

sanjaytripathi.230@rediffmail.com9568004650

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026